v3.19.3
Note 1 - Organization and Basis of Presentation (Details Textual)
1 Months Ended
May 03, 2019
Oct. 11, 2018
Aug. 31, 2019
USD ($)
May 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Stockholders' Equity Note, Stock Split, Conversion Ratio   0.0359            
Cash and Cash Equivalents, at Carrying Value, Ending Balance         $ 331,000 $ 1,887,000 $ 1,760,000 $ 4,301,000
Loans Payable, Total           4,200,000    
Retained Earnings (Accumulated Deficit), Ending Balance         $ (46,312,000) $ (37,279,000)   $ (31,294,000)
Proceeds from Notes Payable, Total       $ 3,200,000        
Majority Investors [Member]                
Debt Instrument, Interest Rate, Stated Percentage         8.00% 8.00%    
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]                
Proceeds from Notes Payable, Total     $ 500,000 $ 5,000,000        
Convertible Debt [Member]                
Notes Payable, Total         $ 6,600,000 $ 4,600,000    
Oxford Finance, LLC [Member]                
Loans Payable, Total         $ 3,000,000      
Alliqua Biomedical, Inc. [Member]                
Business Acquisition, Exchange Ratio 0.0359              
Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]                
Stockholders' Equity Note, Stock Split, Conversion Ratio 6